Thursday, July 22, 2010


****** FDA Advisory Panel Recommends End to Avastin for Advanced Breast Cancer

Avastin for breast cancer – no evidence of improved overall survival, no improvement in quality of life, serious side effects, all at $50k a year. We didn't think this was an improvement for women needing treatment for breast cancer, and as of yesterday, neither does the FDA’s Advisory Committee. Although we’re in agreement with the committee’s recommendation, we’re saddened that after all this time there is still nothing helpful to offer patients when current treatments have failed. We hope the pharma industry takes this message to heart and can find treatments that truly make a difference for all in need.

Check out the full story at

No comments:

Post a Comment